Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Interest Expenses (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Interest Expenses for 9 consecutive years, with $3.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest Expenses rose 57.14% year-over-year to $3.1 million, compared with a TTM value of $8.8 million through Dec 2025, down 6.97%, and an annual FY2025 reading of $7.7 million, down 29.79% over the prior year.
  • Interest Expenses was $3.1 million for Q4 2025 at Enanta Pharmaceuticals, up from $2.4 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $3.4 million in Q4 2023 and bottomed at $1.6 million in Q2 2025.
  • Average Interest Expenses over 3 years is $2.4 million, with a median of $2.4 million recorded in 2025.
  • The sharpest move saw Interest Expenses crashed 42.98% in 2024, then surged 57.14% in 2025.
  • Year by year, Interest Expenses stood at $3.4 million in 2023, then plummeted by 42.98% to $2.0 million in 2024, then surged by 57.14% to $3.1 million in 2025.
  • Business Quant data shows Interest Expenses for ENTA at $3.1 million in Q4 2025, $2.4 million in Q3 2025, and $1.6 million in Q2 2025.